{"id":1616,"date":"2011-12-01T12:03:00","date_gmt":"2011-12-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/nikotinsaeure-zusaetzlich-zu-simvastatin-bei-kardiovaskulaeren-erkrankungen-wieder-nur-lipidkosmetik"},"modified":"2011-12-01T12:03:00","modified_gmt":"2011-12-01T11:03:00","slug":"nikotinsaeure-zusaetzlich-zu-simvastatin-bei-kardiovaskulaeren-erkrankungen-wieder-nur-lipidkosmetik","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/nikotinsaeure-zusaetzlich-zu-simvastatin-bei-kardiovaskulaeren-erkrankungen-wieder-nur-lipidkosmetik","title":{"rendered":"Nikotins\u00e4ure zus\u00e4tzlich zu Simvastatin bei kardiovaskul\u00e4ren Erkrankungen \u2013 wieder nur Lipidkosmetik"},"content":{"rendered":"<p>Mit der ARBITER 6-HALTS-Studie schien vor zwei Jahren die Auferstehung der Nikotins\u00e4ure (Niacin; NIS) in der Therapie der Arteriosklerose eingel\u00e4utet worden zu sein: Im Vergleich zu Statin plus Ezetimib (Ezetrol\u00ae) f\u00fchrte Statin plus NIS zu einer signifikanten Abnahme der Intima-Media-Dicke (1). Unsere kritische Beurteilung von damals (2) wird durch eine neue Studie gest\u00fctzt. In der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mit der ARBITER 6-HALTS-Studie schien vor zwei Jahren die Auferstehung der Nikotins\u00e4ure (Niacin; NIS) in der Therapie der Arteriosklerose eingel\u00e4utet worden zu sein: Im Vergleich zu Statin plus Ezetimib (Ezetrol\u00ae) f\u00fchrte Statin plus NIS zu einer signifikanten Abnahme der Intima-Media-Dicke (1). Unsere kritische Beurteilung von damals (2) wird durch eine neue Studie gest\u00fctzt. In der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3759,1272,3758,451,449,455,3762,453,498,3760,456,664,3763,662,3761,505,443,3757],"class_list":["post-1616","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aim-high-studie","tag-arteriosklerose","tag-atherosklerose","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-hmg-coa-reduktase-hemmer","tag-hps2-thrive-studie","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-laropiprant-plus-nikotinsaeure","tag-lipidsenker","tag-niacin","tag-niacin-plus-laropiprant","tag-nikotinsaeure","tag-nikotinsaeure-plus-laropiprant","tag-simvastatin","tag-statine","tag-tredaptive"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1616"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1616\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}